Daniel Rabinowitz, serving as the Secretary and Chief Legal Officer for Natera, Inc. (NASDAQ:NTRA), completed a transaction involving the sale of 16,800 shares of the company's common stock. This activity was recorded on July 1, 2026. The total value of the shares sold was approximately $4,574,430. The execution of the sale occurred at varying price points, with shares transacting between $266.79 and $278.77 per share.
The disposition of these shares was carried out in accordance with a Rule 10b5-1 trading plan. Mr. Rabinowitz originally established this automated trading arrangement on December 5, 2025. Following the completion of this recent transaction, Mr. Rabinowitz maintains a direct holding of 172,294 shares of Natera common stock.
The timing of this executive sale coincides with a period of robust market performance for Natera. The stock was trading near its 52-week high of $288.04 at the time of the report. Over the preceding year, the equity has delivered a substantial return of 79%. Despite this strong price appreciation, data from InvestingPro analysis indicates that the stock may be trading at a premium relative to its Fair Value estimate. This valuation metric places Natera among companies categorized on the "Most Overvalued" list according to that specific analytical framework.
Operational developments at Natera have been significant and wide-ranging. The company announced that its Signatera test has successfully received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency. This milestone marks the Signatera test as the first molecular residual disease test to achieve PMDA approval in Japan for the treatment of colorectal cancer.
Furthermore, Natera has entered into a partnership with Aveta Biomics to support a Phase 3 clinical trial. This trial will evaluate the efficacy of APG-157 in patients diagnosed with head and neck squamous cell carcinoma. The collaboration will utilize the Signatera test to assess molecular residual disease and monitor treatment response. In parallel, research published in JAMA Oncology highlighted the Signatera test. This study evaluated the test's efficacy in predicting chemotherapy benefits for patients with liver cancer.
Analyst sentiment surrounding Natera has also shifted positively. BTIG raised its price target for the stock to $270. This adjustment was driven by the inclusion of Signatera in the NCCN guidelines for muscle-invasive bladder cancer. Additionally, Bernstein SocGen Group resumed coverage on Natera, assigning an outperform rating. The firm cited expected growth in minimal residual disease testing volumes and improved reimbursement as key factors supporting this outlook.
Market data reflects continued investor interest in the equity. The stock closed at 283.80, representing a gain of 4.48 or 1.60%. After-hours trading showed the price at 284.31, an increase of 0.51 or 0.18%. These developments collectively underscore Natera's expanding influence within the cancer diagnostics sector.